Loading...
Loading...
XOMAP| Name | Value |
|---|---|
| Revenues | 1,490.0K |
| Cost of Revenue | 2.0K |
| Gross Profit | 1,488.0K |
| Operating Expense | 8,492.0K |
| Operating I/L | -7,004.0K |
| Other Income/Expense | -1,591.0K |
| Interest Income | 0.0K |
| Pretax | -8,595.0K |
| Income Tax Expense | -41.3K |
| Net Income/Loss | -8,595.0K |
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring potential future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets, and it helps biotech companies enhance human health by providing financial support and expertise in the development of therapeutic candidates.
